Baricitinib is an oral, specific, and reversible JAK1 and JAK2 inhibitor authorized for the management of rheumatoid arthritis, atopic dermatitis, and severe alopecia areata in many countries14,15. The gene discussed is JAK2; the disease is atopic eczema.